Zhang B.,National Key Laboratory of Breast Cancer Prevention and Treatment |
Zhang F.,Tianjin Key Laboratory of Cancer Prevention and Treatment |
Zhang L.,Tianjin Key Laboratory of Cancer Prevention and Treatment |
Niu R.,Tianjin Key Laboratory of Cancer Prevention and Treatment |
And 6 more authors.
Cancer Science | Year: 2010
Protein interacting with C α kinase 1 (PICK1), which interacts with multiple different proteins in a variety of cellular contexts, is believed to play important roles in diverse pathological conditions including cancer. In this study, we attempted to investigate the correlation of PICK1 with clinicopathological features as well as prognosis of human breast cancer. In addition, we aimed at a better understanding of the biological function of PICK1 in breast cancer cell biology. As judged by semi- quantitative RT-PCR and western blotting, PICK1 was overexpressed in tumor cells as compared to adjacent normal epithelia in breast, lung, gastric, colorectal, and ovarian cancer. As judged by immunostaining breast cancer tissue microarrays, high levels of PICK1 expression correlated with shortened span of overall survival (OS). Protein interacting with C α kinase 1 (PICK1) expression seemed to be specifically associated with reduced OS in lymph node-positive, Her/neu-2 positive, and the basal-like type subgroups, respectively. Consistently, the expression of PICK1 correlated with histological grade, lymph node metastasis, Her-2/neu-positivity, and triple-negative basal-like breast cancer. Protein interacting with C α kinase 1 (PICK1) was not correlated with menopausal status, tumor size, or hormone receptor status. In a complementary study, transfection of MDA-MB-231 cells with PICK1 siRNA decreased cell proliferation and colony formation in vitro and inhibited tumorigenicity in nude mice. Our clinical and experimental evidence supports an oncogenic role of PICK1 in human breast cancer. In particular, our data suggest that PICK1 promotes tumor cell proliferation. Taken together, PICK1 may serve not only as a marker for poor prognosis, but also as a therapeutic target in breast cancer. (Cancer Sci 2010). © 2010 Japanese Cancer Association.